French study aims to uncover hidden patterns in rare kidney disease
NCT ID NCT04326218
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is gathering information from 400 adults in France diagnosed with membranous nephropathy, a rare kidney condition. Researchers will track how the disease progresses over one year, looking at remission rates and possible environmental or genetic risk factors. The goal is to better understand the disease, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nice, Hôpital de l'Archet
RECRUITINGNice, Alpes Maritime, 06200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can a single drug calm lupus kidney disease without a cocktail of meds?
- Immune cells may hold key to predicting kidney disease relapse
- New antibody targets hidden plasma cells to treat kidney disease
- Could a diabetes drug tame the immune system in kidney disease?
- Personalized interferon therapy aims to tame kidney disease without weakening defenses